ReviewGenes & diseases2024
DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects.
Review in Genes & diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
- Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics.Clinical epigenetics · 2026Article
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Association ofTranslational cancer research · 2026Article
- DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.Cancers · 2026Review
- Article
- Plasma-based digital PCR assay for early detection of gastric cancer using multiple methylation biomarkers.Scientific reports · 2025Article
- Cell-Free DNA Methylation-Based Liquid Biopsy Assay to Identify Lymph Node Metastasis in T1 Gastric Cancer.United European gastroenterology journal · 2025Article
- ComprehensiveOncology reports · 2025Review
- DNMT1 blocks SOX21-repressed CKS2 transcription to promote gastric cancer progression.BMC cancer · 2025Article
- Article
- Simulation-guided pan-cancer analysis identifies a novel regulator of CpG island hypermethylation heterogeneity.Briefings in bioinformatics · 2025Article
- Identification of CKAP2 as a Potential Target for Prevention of Gastric Cancer Progression: A Multi-Omics Study.International journal of molecular sciences · 2025Article
- COL1A1, COL1A2, CHN1, and FN1 Promote Tumorogenesis and Act as Markers of Diagnosis and Survival in Gastric Cancer Patients.Current pharmaceutical biotechnology · 2025Article
- Article
- Research Progress of Liquid Biopsy Based on DNA Methylation in Tumor Diagnosis and Treatment.Biomolecules · 2024Review
- Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer.Scientific reports · 2024Article
- Article
- DNA methylation biomarkers for early detection of gastric and colorectal cancers.Cancer biology & medicine · 2024Article
- Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis: A Meta-analysis.International journal of molecular and cellular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most common and deadly cancers worldwide. Early detection offers the best chance for curative treatment and reducing its mortality. However, the optimal population-based early screening for GC remains unmet. Aberrant DNA methylation occurs in the early stage of GC, exhibiting cancer-specific genetic and epigenetic changes, and can be detected in the media such as blood, gastric juice, and feces, constituting a valuable biomarker for cancer early detection. Furthermore, DNA methylation is a stable epigenetic alteration, and many innovative methods have been developed to quantify it rapidly and accurately. Nonetheless, large-scale clinical validation of DNA methylation serving as tumor biomarkers is still lacking, precluding their implementation in clinical practice. In conclusion, after a critical analysis of the recent existing literature, we summarized the evolving roles of DNA methylation during GC occurrence, expounded the newly discovered noninvasive DNA methylation biomarkers for early detection of GC, and discussed its challenges and prospects in clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.